

1 **Full Title: Correlation between blood and CSF compartment cytokines and chemokines in**
2 **subjects with cryptococcal meningitis.**

3

4 **Short Title: Compartment specific cytokine immune environments during infection**

5

6 Elizabeth C Okafor¹, Katherine H Hullsieck², Darlisha A Williams^{1,3}, James E Scriven⁴, Joshua
7 Rhein^{1,3}, Henry W Nabeta³, Abdu K Musubire³, Radha Rajasingham¹, Conrad Muzoora⁵,
8 Charlotte Schutz⁴, Graeme Meintjes⁴, David B Meya^{1,3}, David R Boulware¹.

9

10 ¹ Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

11 ² School of Public Health, University of Minnesota, Minneapolis, MN, USA

12 ³Infectious Diseases Institute, Makerere University, Kampala, Uganda.

13 ⁴ Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease
14 and Molecular Medicine, and Department of Medicine, University of Cape Town, South Africa.

15 ⁵ Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.

16

17 **Corresponding Author:**

18 Elizabeth Okafor

19 Microbiology Research Facility 4-103

20 689 23 rd Ave SE

21 Minneapolis, MN 5455 USA

22 **Email:** okafo039@umn.edu

23

24 **Alternate:** David Boulware boulw001@umn.edu

25

26

27 **ABSTRACT**

28 **Background:**

29 Though peripheral blood is a crucial sample to study immunology, it is unclear whether the
30 immune environment in the peripheral vasculature correlates with that at the end-organ site of
31 infection. Utilizing cryptococcal meningitis as a model, we investigated the correlation between
32 serum and cerebrospinal fluid biomarkers over time.

33

34 **Methodology and Principal Findings:**

35 We analyzed the cerebrospinal fluid and serum of 160 subjects presenting with first episode
36 cryptococcal meningitis for soluble cytokines and chemokines measured by Luminex assay.
37 Specimens were collected at meningitis diagnosis, 1-week, and 2-weeks post cryptococcal
38 diagnosis. We compared paired samples by Spearman correlation and the p-value was set at
39 <0.01. Of the 21 analytes tested at baseline, there was no correlation detected between nearly
40 all analytes. A weak negative correlation was found between serum and cerebrospinal fluid
41 levels of interferon-gamma ($\text{Rho} = -0.214$, $p = .007$) and interleukin- 4 ($\text{Rho} = -0.232$, $p = .003$).
42 There was no correlation at 1-week post cryptococcal diagnosis. However, at 2-weeks post
43 diagnosis, there was a weak positive correlation between levels of granulocyte-macrophage
44 colony-stimulating factor ($\text{Rho} = 0.25$, $p = .007$) between serum and cerebrospinal fluid. No
45 cytokine or chemokine showed consistent correlation overtime.

46

47 **Conclusion and Significance:**

48 Based on our analysis of 21 biomarkers, serum and cerebrospinal fluid immune responses do
49 not correlate. There appears to be a distinct immune environment in terms of soluble
50 biomarkers in the vasculature versus end-organ site of infection. While this is a model of HIV-
51 related cryptococcal meningitis, we postulate that assuming the blood compartment is
52 representative of the immune function at the end-organ site of infection may not be appropriate.

53 **Author Summary:**

54 In subjects with localized infections, peripheral blood is often used as a surrogate to
55 investigate the immune environment at the end-organ site of infection. Sampling the end-organ
56 site of infection is not routinely performed. The current project serves to fill in the gap of
57 knowledge regarding whether the peripheral blood and end-organ site of infection immune
58 environments correlate. Due to therapeutic lumbar punctures in cryptococcal meningitis, we are
59 able to readily sample the cerebrospinal fluid to investigate compartment specific immune
60 responses by quantifying cytokine and chemokine levels. We determined that there was no
61 correlation between peripheral blood and cerebrospinal fluid cytokine levels. The findings from
62 this work serve to caution the use of peripheral blood as a surrogate for compartment specific
63 immune responses. Though our findings are solely from subjects with cryptococcal meningitis,
64 more research should be performed in other compartment specific infections such as
65 pneumonia, osteomyelitis, or hepatitis for validation. Underestimating or overestimating the
66 activation of the immune response at the end-organ site may impact clinical care and prognosis,
67 especially if immunomodulating agents are being considered as therapy; thus, determining
68 whether peripheral blood and end-organ site of infection immune environments correlate is
69 imperative.

70

71

72 **Word Count:** Abstract - 260 words; Author Summary - 194; Manuscript – 1529

73

74

75 **INTRODUCTION:**

76

77 Immunologic investigations are critical to understanding the pathogenesis of infectious
78 disease. Often human or animal subjects have their blood drawn to assess cell phenotype,
79 function, or soluble cytokines or chemokines in order to characterize the immune response to
80 infection. Blood is a convenient and available compartment to analyze. However, it is unclear if
81 analysis of cells trafficking in the peripheral vasculature reflects the actual immune response at
82 the end organ site compartment (e.g. CSF in meningitis, lung in pneumonia). This is important
83 because the end organ site of infection is often the primary site from which initial or disease-
84 specific signs and symptoms manifest. Of even more concern is the possibility of unknowingly
85 overestimating or underestimating the immune response based on analysis of immune cells in
86 the vasculature.

87

88 Analysis of site-specific immune responses in humans is difficult but not impossible.
89 Cryptococcal meningitis is one model which allows investigation of the compartment-specific
90 immune responses. In cryptococcal meningitis, frequent therapeutic lumbar punctures to control
91 intracranial pressure provide a large volume of CSF over the course of treatment. Analysis of
92 CSF provides information about the immune responses in the central nervous system (CNS).
93 Yet, cryptococcal meningitis is not solely a localized CNS infection, but a systemic infection
94 whereby inhaled cryptococcal spores germinate in the lung and yeast cells disseminate via the
95 blood throughout the body (1, 2). Peripheral blood mononuclear cells, serum, and plasma
96 provide information about immune responses in the peripheral vascular compartment.

97

98 In cryptococcosis, but more broadly in infectious disease, the correlation between the
99 immune response in the peripheral vasculature versus immune response in the end-organ
100 compartment is poorly characterized and should be elucidated. We aim to determine the

101 correlation between 21 peripheral blood and CSF cytokines and chemokines in a cohort of
102 subjects with first episode cryptococcosis. Utilizing three distinct time points, we analyzed the
103 correlation between peripheral blood and CSF over time. The results from this analysis serves
104 to fill the gap in knowledge regarding the correlation between immune responses, particularly
105 soluble cytokines and chemokines, in the vasculature and tissue compartments utilizing
106 cryptococcal meningitis as a representative model.

107

108 **METHODS**

109

110 Subjects with first episode of cryptococcal meningitis were originally enrolled in the
111 Cryptococcal Optimal ART Timing (COAT) trial from November 2010 to April 2012 to determine
112 the optimal time to initiate antiretrovirals after cryptococcal meningitis (3). The COAT trial was
113 conducted at: Mulago Hospital, Kampala, Uganda; Mbarara University of Science and
114 Technology, Mbarara, Uganda; and the former G.F. Jooste Hospital in Cape Town, South
115 Africa. All subjects completed written informed consent and the institutional review board from
116 each organization approved the study protocol. Details regarding this study trial have been
117 previously described (Clinicaltrials.gov Identifier No: NCT01075152) (3).

118

119 We collected peripheral blood and CSF samples at cryptococcal meningitis diagnosis,
120 trial randomization at 1-week, and 2-weeks post cryptococcal meningitis diagnosis for cytokines
121 and chemokine analysis. Serum and CSF were analyzed in a targeted multiplex panel for 19
122 cytokines and chemokines using a Luminex multiplex cytokine panel (Bio-Rad, Hercules, CA)
123 (4), following the manufacturer's instructions being run at 1:2 dilution taking the average of two
124 replicates. We also measured CD14 and CD163 by ELISA (R&D Systems, Minneapolis, MN).
125 We have previously reported the longitudinal CSF changes by trial arm (4).

126

127 As secondary analysis, we assessed the correlation, after log transformation of raw
128 readout, between the intra-subject matched serum and CSF using non-parametric Spearman
129 correlation. Data at each time point represents all subjects included in the previous study
130 irrespective of trial arm randomization. Changes in cohort size represents fluctuations in
131 specimen availability, most often due to subjects who declined therapeutic lumbar punctures or
132 subjects who unfortunately died. Significance was set at a p-value of 0.01 to adjust for multiple
133 comparisons in a post-hoc exploratory analysis.

134

135 RESULTS

136

137 Of 177 ART-naïve subjects with first episode of cryptococcal meningitis enrolled into the
138 COAT trial, matching CSF and serum existed for 160 subjects at baseline, 105 subjects at 1-
139 week, and 115 subjects at 2-weeks. Missing specimens were most often due to lack of CSF
140 collection on the same day as serum collection as subjects could refuse therapeutic lumbar
141 punctures. Clinical and demographic data comparing COAT trial arms (early versus late ART
142 initiation) have been previously described (4). Of the 160 subjects included, 79 subjects (49%)
143 were female. The median age was 35 (interquartile range (IQR) 28.5 to 40) years with a median
144 CD4 count of 25 (IQR 10 to 74) cells/ μ L determined at 1-week post diagnosis.

145

146 We assessed whether there was a correlation between immune biomarkers in CSF
147 versus serum for 21 analytes irrespective of study arm randomization. At time of diagnosis,
148 none of the 21 immune biomarkers had a positive correlation by Spearman's non-parametric
149 test (**Table 1**). Two analytes had statistically significant but weak negative correlations; the type
150 1 T-helper cell (Th₁) cytokine interferon-gamma (IFN- γ , Rho= -0.214, p=.007) and the type 2 T-
151 helper cell cytokine (Th₂) interleukin-4 (IL-4, Rho= -0.232, p=.003). While statistically significant,

152 the correlations were relatively weak and inverse for both IFN- γ and IL-4 (**Figure 1**), meaning as
153 blood levels increased, CSF levels decreased.

154

155 Of the 19 biomarkers analyzed among 105 paired samples at 1-week post cryptococcal
156 meningitis diagnosis, no cytokines or chemokines were statistically correlated. Of the 21
157 biomarkers analyzed at 2-weeks post diagnosis among 115 paired samples, a weak positive
158 correlation existed between serum and CSF levels of granulocyte-macrophage colony-
159 stimulating factor (GM-CSF, Rho=0.25, p=.007). Across the three time points as subjects
160 continued standard antifungal therapy, there were no immune biomarkers that were consistently
161 positively or negatively correlated between blood and CSF (**Table 2**). Additionally, analysis of
162 rate of change over time, through slope calculation across all three time points, demonstrated
163 no significant positive or negative correlation between blood and CSF (**Table 2**).

164

165 **DISCUSSION**

166

167 We hypothesized that immune biomarkers would have a general positive correlation
168 between serum and CSF. Surprisingly, we found no consistent correlation between soluble
169 immune biomarkers in the peripheral vasculature versus at the site of infection in the CSF. The
170 cytokine environment was strikingly different, even though cryptococcosis is a disseminated
171 infection throughout the vasculature, lungs, and CNS (2, 5, 6). Additionally, no single analyte
172 had a significant correlation pattern over the course of the first two weeks of standard antifungal
173 therapy. The results from this focused analysis provide evidence that peripheral blood analytes
174 are not necessarily similar to CSF analytes. This builds upon our previous findings which
175 demonstrated that lymphocyte populations and activation levels in CSF are distinct from
176 peripheral blood (7).

177

178 There is a large body of published literature comparing human peripheral blood and CSF
179 cytokines and chemokines across various infectious etiologies of meningitis. Comparatively,
180 little literature has been published regarding the correlation within the same individuals' between
181 human tissue compartments and peripheral blood analytes in infectious etiologies of meningitis
182 (8) or other conditions. Additionally, prior to this study, there was no literature characterizing
183 CSF and blood analyte correlations over time in subjects with cryptococcal meningitis.

184

185 Employing cryptococcal meningitis as a model of compartmentalization, we raise a
186 fundamental question of whether the immunology observed in peripheral blood represents what
187 occurs at the end-organ site of infection. This is particularly important as the infectious disease
188 field continues to consider the potential benefits and risks of immunomodulating agent adjuvant
189 therapy, such as administration of proinflammatory cytokines and/or monoclonal antibodies to
190 inhibit anti-inflammatory cytokines or exhaustion receptor engagement. Therefore, it is crucial to
191 truly understand the immune environment at the end-organ site of infection.

192

193 The effector immune response at the site of infection appears to be very different from
194 that of cells trafficking in blood. Previous studies on cryptococcal meningitis immune
195 reconstitution inflammatory syndrome documented differential expression of leukocyte
196 phenotype when comparing peripheral blood to the CSF (7). We doubt these findings are
197 unique to cryptococcosis, for example as demonstrated by differential gene expression when
198 comparing pericardial fluid to peripheral blood in subjects with pericardial tuberculosis (9). There
199 is also the potential impact of tissue niche on leukocyte activation and cytokine environment.
200 Research on compartmentalization in infection is limited and thus characterizing the immune
201 response in peripheral blood vs end-organ compartments should be rigorously assessed in
202 other localized infections.

203

204 Our study is restricted to immunocompromised persons with cryptococcosis, thus
205 whether the lack of correlation between tissue-specific and peripheral vasculature compartment
206 immune responses is universal, requires future study. Though 160 subjects were included in the
207 baseline analysis, our data are limited by the absence of 35% and 30% of study participants'
208 specimens at 1 and 2 weeks, respectively. However, we postulate that more specimens would
209 not have changed the generally poor strength of the correlations. The strength of correlations for
210 all analytes was generally weak with Rho correlation coefficient ranging from -0.23 to +0.25.
211 Thousands of specimens may have been able to generate a statistically significant p-value, but
212 the correlations were weak. Additionally, a more stringent and formal p-value calculation, (for
213 example Bonferroni correction or Benjamini-Hochberg procedure) would not have changed the
214 overall weak correlation.

215

216 In conclusion, we demonstrate that cytokines and chemokines released upon leukocyte
217 activation do not correlate between serum and CSF in cryptococcal meningitis. This
218 demonstrates that, though readily available, utilizing peripheral blood as an approximation for
219 the immune status in tissue compartments, such as the CNS, is potentially unreliable.

220

221

222

223

224

225

226

227

228

229

230 **Acknowledgements:** We thank the medical officers, nurses, and laboratory staff who were a
231 part of the COAT Trial Study Team. Additionally, we express our deepest gratitude to all study
232 participants and their families, healthcare professionals who provided care for study
233 participants, and laboratory staff at all study sites.

234

235 **Disclaimer:** The findings from this project have not been previously presented at any
236 conferences and has not been previously published.

237

238 **Potential Conflict of Interest:** The authors have declared that no competing interests exist.

239

240

241

242

243

244 **References**

- 245
- 246 1. Coelho C, Bocca AL, Casadevall A. The Intracellular Life of *Cryptococcus neoformans*.
247 Annu Rev Pathol. 2014;9:219-38.
- 248 2. Denham ST, Brown JCS. Mechanisms of Pulmonary Escape and Dissemination by
249 *Cryptococcus neoformans*. Journal of Fungi. 2018;4(25).
- 250 3. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsieck K, Musubire A, et al.
251 Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med.
252 2014;370(26):2487-98.
- 253 4. Scriven JE, Rhein J, Hullsieck KH, von Hohenberg M, Linder G, Rolfes MA, et al. Early
254 ART after cryptococcal meningitis is associated with cerebrospinal fluid pleocytosis and
255 macrophage activation in a multisite randomized trial. J Infect Dis. 2015;212(5):769-78.
- 256 5. Vanherp L, Ristani A, Poelmans J, Hillen A, Lagrou K, Janbon G, et al. Sensitive
257 bioluminescence imaging of fungal dissemination to the brain in mouse models of
258 cryptococcosis. Dis Model Mech. 2019;12(6):dmm039123.
- 259 6. Nicola AM, Robertson EJ, Albuquerque P, Derengowski LdS, Casadevalla A. Nonlytic
260 Exocytosis of *Cryptococcus neoformans* from Macrophages Occurs In Vivo and Is Influenced by
261 Phagosomal pH. mBio. 2011;2(4):e00167-11.
- 262 7. Meya DB, Okurut S, Zziwa G, Rolfes MA, Kelsey M, Cose S, et al. Cellular immune
263 activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune
264 reconstitution inflammatory syndrome. J Infect Dis. 2015;211(10):1597-606.
- 265 8. Fassbender K, Schminke U, Ries S, Ragoschke A, Kischka U, Fatar M, et al.
266 Endothelial-derived adhesion molecules in bacterial meningitis: association to cytokine release
267 and intrathecal leukocyte-recruitment. J Neuroimmunol. 1997;74(1-2):130-4.
- 268 9. Matthews K, Deffur A, Ntsekhe M, Syed F, Russell JBW, Tibazarwa K, et al. A
269 Compartmentalized Profibrotic Immune Response Characterizes Pericardial Tuberculosis,
270 Irrespective of HIV-1 Infection. Am J Respir Crit Care Med. 2015;192(12):1518-21.
- 271
- 272

273 **Table 1: Correlation of Paired CSF and Serum Analytes at Baseline, 1-Week, and 2-Weeks**
274 **post Cryptococcal Meningitis Diagnosis.**

275

Biomarker	At CM diagnosis			1-week post diagnosis			2-weeks post CM diagnosis		
	N	Rho	P-value	N	Rho	P-value	N	Rho	P-value
<i>Innate Immune response</i>									
IL-6	160	0.021	0.79	105	-0.025	0.80	115	-0.228	0.01
IL-1 β	160	-0.042	0.60	105	-0.122	0.22	115	0.052	0.58
IL-8	160	-0.034	0.67	105	0.141	0.15	115	0.035	0.71
G-CSF	160	-0.003	0.97	105	0.1	0.31	115	0.087	0.36
GM-CSF	160	0.033	0.68	105	0.16	0.10	115	0.25	0.007*
MCP-1	160	0.133	0.09	105	0.216	0.03	115	-0.117	0.21
MIP-1 α	75	0.01	0.93	5	0.4	0.51	93	-0.07	0.51
MIP-1 β	160	0.117	0.14	105	0.114	0.25	115	-0.057	0.55
CD14	87	0.078	0.47	n	N/A	N/A	83	0.187	0.09
CD163	87	-0.249	0.02	n	N/A	N/A	83	-0.099	0.38
<i>Adaptive Immune response</i>									
IFN- γ	160	-0.214	0.007*	105	0.089	0.37	115	0.198	0.03
TNF- α	160	0.077	0.33	105	0.038	0.70	115	0.078	0.41
IL-12	160	0.09	0.26	105	-0.153	0.12	115	-0.005	0.96
IL-2	160	-0.025	0.76	105	-0.041	0.68	115	0.22	0.02
IL-7	160	0.038	0.64	105	0.11	0.26	115	-0.004	0.96
IL-10	160	0.021	0.80	105	0.045	0.65	115	-0.025	0.80
IL-5	160	-0.046	0.56	105	0.099	0.32	115	0.004	0.97
IL-4	160	-0.232	0.003*	105	0.107	0.28	115	-0.064	0.49
IL-13	160	0.056	0.48	105	-0.004	0.97	115	-0.057	0.54
IL-17	160	-0.008	0.92	105	0.128	0.19	115	0.012	0.90
<i>Hemostasis</i>									
VEGF	111	-0.049	0.61	62	0.062	0.63	115	-0.002	0.99

276

277 *P value of less than 0.01.


278 Interleukin (IL), Interferon (IFN), Tumor- necrosis factor (TNF), Granulocyte-colony stimulating factor (G-CSF),

279 Granulocyte-macrophage colony stimulating factor (GM-CSF), Monocyte chemoattractant protein-1/CCL2 (MCP-1),

280 Macrophage inflammatory protein (MIP), and Vascular Endothelial Growth Factor (VEGF)

281

282 **Figure 1: Scatterplot of Interferon-Gamma (IFN- γ) and Interleukin-4 (IL-4) at Cryptococcal
283 Meningitis in CSF Versus Serum.**
284



285
286 IFN- γ is a Th₁ cytokine which is protective in cryptococcosis causing classical activation of macrophages to enhance
287 killing of yeast. IL-4 is Th₂ cytokine which is not protective in mouse models of cryptococcosis. Both cytokines have a
288 weak, inverse correlation between levels observed in serum versus CSF. Levels are in pg/mL.
289

290 **Table 2. Correlation of CSF and Serum Cytokines Pooled Across All Three Time Points**
291 **at Baseline, 1-Week, and 2-Weeks post Cryptococcal Meningitis Diagnosis.**
292

BIOMARKER	N	Rho	P-value	N	Rho	P-value
<i>Combined Correlation</i>						<i>Rate of Change Over Time</i>
<i>Innate Immune response</i>						
IL-6	403	-0.07	0.16	160	0.151	0.06
IL-1 β	403	0.029	0.57	160	0.070	0.38
IL-8	403	0.029	0.56	160	0.132	0.10
G-CSF	403	0.067	0.18	160	0.086	0.28
GM-CSF	403	0.147	0.003*	160	-0.030	0.70
MCP-1	403	0.073	0.15	160	0.111	0.16
MIP-1 α	214	-0.127	0.06	118	0.061	0.51
MIP-1 β	403	0.10	0.05	160	-0.119	0.13
CD14	312	0.095	0.09	128	0.180	0.04
CD163	312	-0.051	0.37	128	-0.143	0.11
<i>Adaptive Immune response</i>						
IFN- γ	403	0.119	0.02	160	0.120	0.13
TNF- α	403	0.102	0.04	160	0.096	0.23
IL-12	403	-0.021	0.67	160	-0.003	0.97
IL-2	403	0.089	0.08	160	-0.057	0.48
IL-7	403	0.036	0.47	160	-0.032	0.69
IL-10	403	-0.062	0.21	160	0.068	0.40
IL-5	403	0.041	0.41	160	0.059	0.46
IL-4	403	0.082	0.10	160	-0.063	0.43
IL-13	403	-0.093	0.06	160	0.194	0.014
IL-17	403	0.066	0.19	160	-0.082	0.30
160						
<i>Hemostasis</i>						
VEGF	307	0.051	0.37	147	-0.059	0.48

293

294 *P value of less than 0.01.

295 Interleukin (IL), Interferon (IFN), Tumor- necrosis factor (TNF), Granulocyte-colony stimulating factor (G-CSF),

296 Granulocyte-macrophage colony stimulating factor (GM-CSF), Monocyte chemoattractant protein-1/CCL2 (MCP-1),

297 Macrophage inflammatory protein (MIP), and Vascular Endothelial Growth Factor (VEGF)

298